Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | GPR142 | Q7Z601 | 3/20 | 0.42 |
| ▸ | WNT3A | P56704 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.38 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.38 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.38 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.38 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.38 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.38 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.38 |
| ▸ | NPY1R | P25929 | 1/20 | 0.38 |
| ▸ | NPY2R | P49146 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2685807 | 1.00 | PKM (0.42) | PKMGPR142WNT3AALDH1A1TP53 | |
| SCHEMBL2686712 | 0.86 | GPR142 (0.47) | GPR142WNT3AMAPK1PSEN1PSEN2 | |
| SCHEMBL2686723 | 0.86 | GPR142 (0.47) | GPR142WNT3AMAPK1PSEN1PSEN2 | |
| SCHEMBL2683720 | 0.78 | GPR142 (0.71) | GPR142 | |
| SCHEMBL2683725 | 0.78 | GPR142 (0.71) | GPR142 | |
| SCHEMBL15875890 | 0.77 | GPR142 (0.44) | GPR142WNT3AMAPK1PSEN1PSEN2 | |
| SCHEMBL6032434 | 0.77 | GPR142 (0.44) | GPR142WNT3AMAPK1PSEN1PSEN2 | |
| SCHEMBL2684336 | 0.77 | GPR142 (0.53) | GPR142WNT3APSEN1PSEN2APH1B | |
| SCHEMBL2685595 | 0.73 | GPR142 (0.52) | GPR142WNT3AMAPK1PSEN1PSEN2 | |
| SCHEMBL2685598 | 0.71 | GPR142 (0.57) | GPR142 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785468-B2 | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions | AMGEN INC. (US) | 2014-07-22 | — | — | US | claimed |
| US-8785468-B2 | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions | AMGEN INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | AMGEN INC. (US) | 2012-05-10 | — | — | US | disclosed |
| WO-2010093849-A2 | PHENYLALANINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | AMGEN INC. (US) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | IAPP, INSR, AMY2A | PKM 916/4885GPR142 2779/4885WNT3A 4600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.